Participated · Series A · Apr 2022

LTZ Therapeutics is advancing a Universal Myeloid Cell Engager (U-MCE™) platform designed to engage and activate monocytes and macrophages to enhance phagocytosis across oncology and autoimmune indications. Its lead asset, LTZ-301, is a bispecific myeloid engager that redirects monocytes and macrophages to deplete CD79b+ B-cells and is actively enrolling patients with relapsed/refractory non-Hodgkin lymphoma in a Phase 1 study; preclinical data showed potent pharmacology and a favorable safety profile. The company is preparing an IND and plans Phase 1 initiation for its second asset, LTZ-232. LTZ has raised approximately $130 million since its founding in 2022 and will use the recent $38 million financing to accelerate clinical development across its pipeline. The company maintains operations in Redwood City, California and Shenzhen, China, and recently added Erin Lavelle to its board to guide strategic operations.

Participated · Series E · Dec 2020

CANbridge Pharmaceuticals develops and commercializes specialty therapeutics for orphan diseases and targeted cancers. The company recently received marketing approval in China for Hunterase (CAN101) to treat Hunter syndrome and approval in Taiwan for NERLYNX (neratinib) for early-stage HER2-positive breast cancer. CANbridge says it has a deep rare disease pipeline and strategic partnerships, including a global partnership with WuXi Biologics and collaborative agreements with the Horae Gene Therapy Center at UMass Medical School for gene therapy research. The company intends to expand its rare disease pipeline through internal development and external partnerships. Planned uses of recent financing include accelerating clinical development of preclinical assets, preparing the commercial launch of CAN101 (Hunterase), and supplementing working capital. CANbridge positions itself as a leader in greater China’s orphan disease market and is focused on commercialization of innovative drugs to address unmet medical needs. CANbridge Pharmaceuticals is a China-focused biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions, with an emphasis on rare genetic diseases and targeted oncology products. Its rare disease pipeline includes Hunterase®, an enzyme replacement therapy for Hunter syndrome, for which CANbridge has filed a New Drug Application in China and plans to commercialize this year. The company has entered the commercial stage with two approved oncology products: Caphosol® in mainland China and NERLYNX® (neratinib) in Hong Kong, and holds exclusive licensing rights to Hunterase® in greater China. CANbridge has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for rare genetic diseases. Proceeds from the financing will be used to accelerate and expand the rare disease pipeline through internal development and external partnerships, build commercial infrastructure and capabilities in China, and supplement working capital. The announcement notes that the majority of the capital raised comes from global investors. CANbridge Life Sciences is a clinical-stage biopharmaceutical company that acquires and develops Western clinical‑stage drugs and devices for commercialization in China and North Asia. Its two lead oncology candidates are CAN008, a fully human fusion onco‑immunotherapy, and CAN017, an ErbB3 (HER3) inhibitory antibody. CAN008 is in a Phase I/II trial for glioblastoma multiforme in Taiwan and the company plans to initiate a Phase II CAN008 GBM trial in China in 2018. CAN017 is being developed to target esophageal squamous cell carcinoma, the prevalent form of esophageal cancer in Asia. CANbridge holds licensing and commercialization agreements with EUSA Pharma (Caphosol), Apogenix (APG101 renamed CAN008) and AVEO Oncology (AV-203 renamed CAN017, ex‑North America). The company is headquartered in Beijing and aims to build a pipeline of specialty oncology candidates addressing unmet needs in the region. CANbridge Life Sciences accelerates development and commercialization of Western clinical-stage pharmaceuticals, medical devices, and diagnostics for China and North Asia (Korea and Taiwan). Founded in 2012 and headquartered in Beijing, the company forms partnerships and licenses exclusive rights from Western biopharmaceutical firms to bring products that are unavailable or address underserved medical needs in the region. CANbridge has an exclusive licensing agreement with U.S.-based Azaya Therapeutics to develop ATI-1123 in China for non-small cell lung cancer and other solid tumors, and an agreement with EUSA Pharma to commercialize Caphosol in China for prevention and treatment of oral mucositis. Prior to the Series A, CANbridge was predominantly funded by angel investment from U.S. and Chinese life-sciences executives. The company intends to use the new funding to expand business development and operations and to more aggressively execute its 'in China for Asia' strategy to bring Western therapies sooner to underserved Asian markets.

Participated · Series C · Oct 2020

Hinova Pharmaceuticals, founded in 2013 and based in Chengdu, discovers, develops, and industrialises drugs targeting metabolic diseases and cancers. Its pipeline includes nine drug candidates, notably HC-1119, an innovative androgen receptor antagonist for metastatic castration-resistant prostate cancer (mCRPC) now in Phase III international multi-centre trials. The company expects HC-1119 to reach the global market in 2022. Hinova said the new financing will support multi-centre clinical trials and the commercialization of its drug candidates domestically and internationally. The firm is also recruiting a chief financial officer with preferred expertise in city board biomedical listings and Hong Kong IPO experience. To date it has completed prior financings including a Series B+ in January 2020 that raised US$32 million from six institutional investors including GF Xinde Investment.

Participated · Series B · Apr 2018

CMAB Biopharma provides bespoke development and manufacturing services for antibodies and biologics, offering process development, analytical methods, formulation, and manufacture of biologic drug substances and products. Led by President Qibin Liang, the company serves clients in China and globally from a facility in Suzhou’s BioBAY Park. The company’s new manufacturing facility will produce pre-clinical and early-stage clinical (Phase I/II) products following global GMP standards. CMAB plans to upgrade its 2,000L GMP facilities and expand capacity to offer 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services. The facility and operations are stated to follow standards of the China Food & Drug Administration, US FDA (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH guidelines. The article reports a recent financing to support these expansion and upgrade plans. CMAB Biopharma is a full-service contract development and manufacturing organization (CDMO) based in BioBAY Park, Suzhou, China, offering process development and manufacturing for biologic products. The company provides development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products. Initial services target generation of pre-clinical and early-stage clinical (Phase I/II) products for Chinese and global clients. CMAB follows global GMP standards, including CFDA, US FDA (21 CFR), EMA (Eudralex), WHO, and harmonized PIC/S and ICH guidelines. Led by President Liang Qibin, the company currently has 65 employees and plans to expand to 180 staff within one year. The business offers bespoke antibody and biologics development and manufacturing services for clients in China and across the globe.